CEO gets "taste of own medicine" by participating in vaccine trial
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.
by albert rønning andersson, translated by catherine brett
CEO of Expres2ion Biotechnologies Bent U. Frandsen had the perfect caption ready when he received his first dose of Bavarian Nordic’s Covid-19 booster candidate while participating in a phase III trial.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Covid-19 jabs as boosters for infants
For subscribers
